Friday, August 28, 2020

ALL session times are listed as EASTERN Standard Time

9:00 am – 10:00 am

GS301 – New Drugs in Dermatology

This presentation will provide an overview of new marketed medications, results of research studies regarding medications, and review new possible indications for older medications.

Learning Objectives:
Explain the responsibility of maintaining knowledge to manage complicated drug regimens for patients.
Identify at least 3 new medications and/or new indications for old medications with details on pharmaceutical indicators, pharmacokinetic and pharmacodynamics for each.
Describe the pathophysiology of at least possible 3 adverse reactions of identified new medications.

Virtual Room V100

Theresa Coyner, MSN, RN, ANP-BC

10:00 am – 10:15 am

Break

10:30 am – 11:30 am

CS311 – Legal Ramifications

This presentation will focus on the essentials of medical malpractice as they apply to nursing and to nurse practitioners.

Learning Objectives:
Explain the primary sources of law and how each affects practice.
Identify significant elements that must be present for a professional to be held liable for malpractice.
Analyze strategies nurses can use to reduce their likelihood of being sued for malpractice.

Virtual Room V100

Whitney High, MD, JD, MEng

10:30 am – 11:30 am

CS312 – Atypical Leg Wounds and Dermatological Nursing: Climbing to New Heights

Leg wounds are often classified based on their etiologies, such as neuropathy, vascular insufficiency, and prolonged pressure. However, not all wounds fall neatly into these categories. It is estimated that approximately 10% of chronic leg wounds are considered atypical, meaning they are the result of an etiology other than neuropathy, vascular insufficiency, or pressure. The purpose of this presentation will be to provide health care clinicians at any level with information to enhance their understanding of atypical leg wounds and to apply principles of wound care toward treatment. Target audience will include nurses at all levels of licensure including but not limited to LPN/LVN, RN, and APRN.

Learning Objectives:
Identify atypical lower leg wounds based on assessment and clinical manifestations.
Differentiate between the different types of wound dressings and their mechanisms of action including clinical application and frequency of usage.
Explain selected topical drug therapy with mechanism of action including clinical application, frequency of usage, and adverse reactions.

Virtual Room V200

Jessica Simmons, MSN, APRN, FNP-C, CWOBm, DNC

11:30 am – 11:45 am

Break

11:45 am – 12:45 pm

GS321 – Transgender Affirming Dermatological Care

LGBTQ+ people have been historically marginalized and historically underserved in health care settings, including dermatology. Through affirming care trainings, Dermatological nurses can make an impact on reducing the frequent disrespect and harassment Transgender and Non-binary patients’ experiences accessing healthcare. This interactive workshop will be presentation-based with ample audience engagement and some space for discussion. Using a trauma informed care framework, we will review relevant terminology such as gender Identity and sex assigned at birth, discuss protocol on how to use and ask affirming name and pronouns, address binary forms such as IPLEDGE, how to ask for a patients affirming anatomical language, and general affirming practices and policy within dermatology settings.

Learning Objectives:
Explain the prevalence of transgender in the general population.
Describe the importance of addressing disparities by equipping primary care providers and health systems with the tools and knowledge to meet the health care needs of their transgender and gender nonconforming patients.
Identify three ways to increase Transgender and Nonbinary affirming practices within Dermatology.

Virtual Room V100

Andrew Miller, MA

12:45 pm – 1:15 pm

Break

1:15 pm – 2:15 pm

CS331 – Cutaneious T-Cell Lymphoma/Mycosis Fungoides

This activity is intended for healthcare professionals involved in the care of patients with Mycosis Fungoides – Cutaneous T Cell Lymphoma (MF-CTCL). The goal of this activity is to assess and summarize the current understanding of CTCL-MF in clinical practice.

Learning Objectives:
Explain the pathophysiology of CTCL-MF.
Assess and summarize the current understanding of CTCL-MF in clinical practice.
Discuss the pharmacodynamics, clinical indications, dosages, and routes of recommended medications used in the treatment of CTCL-MF.

Virtual Room V100

Theresa Pacheco, MD

1:15 pm – 2:15 pm

CS332 – Female Pattern Hair Loss (FPHL); Clinical Evaluation, Testing and Treatment

Female pattern hair loss is a common “reason for visit” in dermatology. The visit can be a very emotional one for our patient due to the high sociocultural value of hair and hair care for many women. Efficient clinical evaluation and knowledgeable treatment are critical to quality treatment planning.

Learning Objectives:
Explain the anatomy of the human hair follicle including physiologic functions.
Identify prudent clinical evaluation methods and testing for femal pattern hair loss (FPHL).
Explore unique medications, differentiating between their mechanisms of action, application methodology or systemic dosing, and potential side effects.

Virtual Room V200

Katrina Nice Masterson, DNP, RN, FNP-BC, DCNP

2:15 pm – 2:30 pm

Break

2:30 pm – 3:30 pm

GS341 – Management of Hidradenitis Suppurativa: a Practical Toolkit Friday

Hidradenitis suppurativa is a debilitating inflammatory disorder of the hair follicles in intertriginous areas. The purpose of this lecture is to provide medical, social, and psychosocial approaches to the management of hidradenitis suppurativa in a case-based format. Discuss the clinical management of hidradenitis suppurativa.

Learning Objectives:
Identify at least three (3) surgical interventions that are considered in cases of hidradenitis suppurativa.
Explain details of the common therapeutic modalities with details on pharmacokinetics, dosage, and actions for topical medications, intralesional injections, systemic medications including oral antibiotics, retinoids and biologics.

Virtual Room V100

Ginette Okoye, MD